Drug Discovery: Reversed-Phase High Pressure Liquid Chromatography for Protein/Peptide Identification

Apr 28, 2012

Scientists typically perform unbiased protein identification by directly coupling reversed-phase high pressure liquid chromatography (HPLC) via electrospray ionisation to a mass spectrometer. Unlike innovations in mass spectrometric instrumentation, cutting-edge technology in reserved-phase HPLC has generally not been well adopted in drug discovery. Remco Swart at Thermo Fisher Scientific describes the effects of increased peak capacities on the number of identified proteins and peptides in complex mixtures utilising an RSLCnano LC system, providing a rationale for using advanced reversed-phase HPLC technology coupled with tandem mass spectrometry (HPLC-MS/MS). ...

Read More

Molecular Imaging in Preclinical Research and Drug Development

Apr 28, 2012

Drug development is a lengthy process; development durations of 10–15 years are commonplace when following the established paradigms. Zheng Jim Wang and Mark R. Lane of MPI Research explain that a recent shift in drug discovery efforts, utilising novel biomarkers against specific molecular targets highlights, has seen the need for robust molecular imaging platforms to provide specific endpoints. ...

Read More

The New Life Science Solution and its Implications on Document Management for Pharmaceutical Companies

Apr 28, 2012

The European Medicines Agency (EMA) recently announced new pharmacovigilance legislation, more commonly known as “the pharmaceutical package”. In this package the EMA describes how to modernise its pharmacovigilance system, how to improve patient safety and how to supply health information to patients. Olaf Schoepke and Gerhard Neurauter at EXTEDO explain how agencies and pharmaceutical companies can address this new legislation, along with the respective consequences for their data management. ...

Read More

United Nations Summit on Non-communicable Diseases

Apr 28, 2012

The NCD epidemic is hitting vulnerable, socially and economically disadvantaged people the hardest. The World Economic Forum’s 2010 Global Risk Report lists NCDs as the second-greatest risk to global economic growth. One half of those who die from NCDs are in their productive years, making the social costs and economic consequences in terms of lost productivity considerable. Rebecca MORTON DOHERTY of Union for International Cancer Control (UICC) discusses that, by having the UN Summit and agreement on a political declaration on NCDs, the process of addressing NCDs globally has been set in motion in the most powerful way. ...

Read More

Personalised Medicine & Companion Diagnostic Device Development

Apr 28, 2012

Healthcare in the developed world is on the edge of a precipice. Populations are aging and healthcare costs are rising against the backdrop of uncertain economic times. Consulting the latest OECD figures shows the cost of healthcare as a percentage of GDP rising from 13.6% to 17.4%. Nick Rollings of Sagentia explores how the pharma industry itself is undergoing a period of intense change. ...

Read More